Table 1.
Patients, tumour and treatment characteristics
| Variables | No. of patients (total: 258) | % |
|---|---|---|
| Age (years) | ||
| Median (range) | 52 (27–83) | |
| Menopausal status | ||
| Premenopausal | 100 | 39 |
| Perimenopausal | 24 | 9 |
| Postmenopausal | 134 | 52 |
| Surgery type | ||
| Modified radical mastectomy | 148 | 57 |
| Breast conserving surgery | 110 | 43 |
| Tumour grade | ||
| Grade 1 | 27 | 11 |
| Grade 2 | 168 | 65 |
| Grade 3 | 63 | 24 |
| Tumour stages | ||
| pT1 | 77 | 30 |
| pT2 | 149 | 58 |
| pT3 | 22 | 8 |
| pT4 | 104 | |
| Lymph node stages | ||
| pN0 | 94 | 36 |
| pN1 | 93 | 36 |
| pN2 | 44 | 17 |
| pN3 | 27 | 11 |
| Hormonal status | ||
| ER (+) PR (+) HER2 (−) | 159 | 62 |
| ER (+) PR (+) HER2 (+) | 53 | 20 |
| ER (−) PR (−) HER2 (+) | 23 | 9 |
| Triple (−) | 23 | 9 |
| ECE | ||
| Yes | 97 | 38 |
| No | 128 | 50 |
| Unknown | 33 | 12 |
| LVI | ||
| Yes | 116 | 45 |
| No | 125 | 48 |
| Unknown | 17 | 7 |
| Ki-67 values | ||
| Low (0–9%) | 46 | 18 |
| Intermediate (10–25%) | 82 | 32 |
| High (>25%) | 130 | 50 |
ER: oestrogen hormone receptor; PR: progesterone hormone receptor; HER2: human epidermal growth factor receptor 2; ECE: extracapsular extension; LVI: lymphovascular invasion